grepafloxacin has been researched along with clarithromycin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jia, L; Sun, H | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dencer, C; Felmingham, D; Ridgway, GL; Robbins, MJ; Salman, H | 1 |
| Frimpong, EK; Honda, T; Voravuthikunchai, SP; Yoh, M | 1 |
| Churchyard, GA; Dylewski, JS; Hagberg, L; Moola, S; Sedani, S; Staley, H | 1 |
| Langan, CE; Marr, C; McIvor, A; Peirzchala, W; Smakal, M; Staley, H; Vogel, F; Zuck, P | 1 |
| Ballow, CH; Forrest, A; Hyatt, JM; Peloquin, CA; Sands, MF; Schentag, JJ; Tran, JQ | 1 |
| Esposito, S; Ianniello, F; Noviello, S | 1 |
| Asherov, J; Dan, M; Poch, F | 1 |
| Cynamon, MH; Sklaney, M; Yeo, AE | 1 |
4 trial(s) available for grepafloxacin and clarithromycin
| Article | Year |
|---|---|
A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 1999 |
Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bronchitis; Clarithromycin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines | 1999 |
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Clarithromycin; Female; Fluoroquinolones; Haemophilus; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Piperazines; Serum Bactericidal Test; Sputum | 2000 |
Crossover assessment of serum bactericidal activity of grepafloxacin, ofloxacin and clarithromycin against respiratory pathogens after oral administration to healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Blood Bactericidal Activity; Clarithromycin; Cross-Over Studies; Female; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Klebsiella pneumoniae; Male; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Piperazines; Respiratory Tract Infections; Streptococcus pneumoniae | 2001 |
9 other study(ies) available for grepafloxacin and clarithromycin
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Fluoroquinolones; Gram-Negative Bacteria; Legionella; Mycoplasma; Ofloxacin; Piperazines; Quinolones; Ureaplasma urealyticum | 1997 |
Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7.
Topics: Animals; Anti-Infective Agents; Azithromycin; Bacterial Toxins; Chlorocebus aethiops; Clarithromycin; Dose-Response Relationship, Drug; Enterotoxins; Erythromycin; Escherichia coli O157; Fluoroquinolones; Humans; Macrolides; Norfloxacin; Piperazines; Quinolones; Shiga Toxin 1; Time Factors; Vero Cells | 1999 |
Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Penicillin Resistance; Piperazines; Quinolines; Streptococcus pneumoniae; Streptococcus pyogenes; Time Factors | 2000 |
The activity of grepafloxacin in two murine models of Mycobacterium avium infection.
Topics: Administration, Intranasal; Animals; Clarithromycin; Disease Models, Animal; Ethambutol; Female; Fluoroquinolones; Injections, Intravenous; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium Complex; Piperazines; Random Allocation; Rifabutin | 2004 |